23G玻璃体切割术前玻璃体腔注射雷珠单抗的临床观察
2016-10-12王建宏张明媚
李 琴,王建宏,张明媚,王 颖
·临床报告·
23G玻璃体切割术前玻璃体腔注射雷珠单抗的临床观察
李琴1,王建宏1,张明媚1,王颖2
1Department of Ophthalmology,the First Affiliated Hospital of Xinjiang Medical University,Urumqi 843054,Xinjiang Uygur Autonomous Region,China;2Department of Ophthalmology,the First Hospital of Aksu Prefecture,Aksu 843000,Xinjiang Uygur Autonomous Region,China
Abstract
•AIM: To analyze the effect of preoperative intravitreal injection of Ranibizumab (IVR) in patients undergoing pars plana vitrectomy (PPV) for proliferative diabetic retinopathy (PDR).
•METHODS:In this retrospective research,62 patients (67 eyes) with PDR in the First Affiliated Hospital of Xinjiang Medical University from Jun.2014 to Jun.2015 were recruited.They were assigned to an experimental group (n=37 eyes) and a control group (n=30 eyes).The patients in experimental group were given 1 injection of IVR (Lucentis 1.0mg/0.1mL) 1wk before surgery,whereas those in control group went down to surgery directly.The average operation time,iatrogenic breaks,the use of tamponade,electric coagulation,and vision increase rate were comparatively analyzed between two groups.
•RESULTS:The average operation time was (91.7±20.8)min in the experimental group vs (117.6±18.6)min in the PPV group(t=-5.314,P<0.05).The rate of electric coagulation (11%) vs (47%),(χ2=8.963,P=0.006); iatrogenic breaks (5%) vs (33%),(χ2=8.789,P=0.004) and silicone oil or inert gas tamponade (27.0%) vs (53.3%),(χ2=4.828,P=0.043).The rate of visual improvement (75.7%) vs (46.7%),(χ2=5.960,P=0.022).There was no severe complication associated with surgery,such as choroidal detachment,retinal detachment and endophthalmitis.
•CONCLUSION:IVR before microincision vitrectomy can effectively shorten the operation time,reduce the use of electric coagulation and intraocular tamponade,and improve the rate of visual improvement for PDR patients.
目的:观察增生型糖尿病视网膜病变(proliferative diabetic retinopathy,PDR)患者玻璃体腔注射雷珠单抗(intravitreal injection of ranibizumab,IVR)对23G玻璃体切割手术疗效的影响。
方法:回顾性病例对照研究。临床确诊为PDR需行23G玻璃体切割手术治疗的患者62例67眼纳入研究。术前7~10d行IVR 治疗者37眼作为注药玻璃体切割组;未行IVR 治疗者30眼作为单纯玻璃体切割组。两组患眼均由同一医生完成23G玻璃体切割手术(pars plana vitrectomy,PPV)。通过手术记录及手术中三方核查表获得术中操作及手术时间,计算并比较分析两组患眼手术中手术时间、电凝、眼内填充物(硅油或惰性气体)使用率以及医源性裂孔发生率。对比分析两组患眼手术后视力提高率。
结果:注药玻璃体切割组、单纯玻璃体切割组手术时间分别为91.7±20.8、117.6±18.6min。注药玻璃体切割组手术时间较单纯玻璃体切割组明显缩短,差异有统计学意义(t =-5.314,P<0.05)。电凝使用率:注药玻璃体切割组为11%,单纯玻璃体切割组为47%,两组比较差异有统计学意义(χ2=8.963,P=0.006);医源性裂孔发生率:注药玻璃体切割组为5%,单纯玻璃体切割组为33%,两组比较差异有统计学意义(χ2=8.789,P=0.004);硅油或气体填充率:注药玻璃体切割组为27%,单纯玻璃体切割组为53%,两组比较差异有统计学意义(χ2=4.828,P=0.043);术后视力提高率:注药玻璃体切割组为76%,单纯玻璃体切割组为47%,两组比较差异有统计学意义(χ2=5.960,P=0.022)。所有患眼均未发生脉络膜脱离、视网膜脱离、眼内炎等严重术后并发症。
结论:PDR患眼23G玻璃体切割手术前IVR 可缩短手术时间、减少术中电凝、眼内填充物的使用率及医源性裂孔发生率,并在一定程度上更好地提高患眼视力。
雷珠单抗; 增生型糖尿病视网膜病变; 玻璃体切割术
引用:李琴,王建宏,张明媚,等.23G玻璃体切割术前玻璃体腔注射雷珠单抗的临床观察.国际眼科杂志2016;16(10):1959-1961
0 引言
球内注射抗血管内皮生长因子(vascular endothelial growth factor,VEGF)药物问世之初主要用于老年性黄斑变性(age-related macular degeneration,AMD)的治疗,目前该治疗手段越来越多被运用于两大致盲性眼病:糖尿病性黄斑水肿(diabetic macular edema,DME)和增生型糖尿病视网膜病变(proliferative diabetic retinopathy,PDR)[1-2]。……
